AML3D (ASX: AL3): Submarine Parts Order Lifts Shares Toward a Key Chart Level
AML3D (ASX: AL3) shares jumped after securing a first US Navy submarine parts order from Austal USA, building on record FY26 revenue. Trading above key support, the stock now tests a technical trigger level, with a confirmed breakout above $0.165 needed to signal further upside.
4DMedical (ASX: 4DX): Pulls Back After Breakout Rally
4DMedical slipped to A$4.57 after its breakout rally, as traders took profit near A$5.00. Momentum remains constructive, but holding A$4.25–A$4.50 is crucial while CT expansion, acquisitions and SaaS growth support the broader story.
4DMedical (ASX: 4DX): Funding Risk Behind the High-Growth MedTech Hype?
4DMedical Limited is an Australian medtech company developing lung imaging software that turns standard scans into functional insights. It has strong growth potential through scalable products like CT:VQ, but remains speculative due to ongoing cash burn, reliance on adoption, and funding risk.
Why KTEK Aerosystems (ASX:KTK) 's $200k Defence Deal Is a Huge Opportunity
KTEK Aerosystems (ASX: KTK) secured its first order from a major Israeli defence prime, a modest US$200,000 milestone within a US$994,100 work package. The real opportunity is a potential US$5 million pipeline, contingent on clearing upcoming engineering reviews and further customer orders.
.webp&w=828&q=75)
AdAlta (ASX: 1AD) $120M Deal: Proof of Platform, Not Profit
While AdAlta (ASX: 1AD) is not the recipient of the $120 million deal, this agreement could do wonders for its IRO technology platform by validating it and making future product development through the platform easier and faster.
4DMedical (ASX: 4DX): Pricing the Future of Lung Imaging
4DMedical is scaling its lung-imaging software portfolio, led by CT:VQ, across hospitals and imaging networks. FY26 scan volumes rose 77% to 344,075, while cash reached A$278m; however, the company remains loss-making as it pursues commercial adoption and revenue growth.